Orchard Therapeutics PLC ORTX
We take great care to ensure that the data presented and summarized in this overview for Orchard Therapeutics plc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ORTX
View all-
Strategic Wealth Advisors Group, LLC Sacramento, CA517KShares$00.01% of portfolio
-
Altium Wealth Management LLC22KShares$00.0% of portfolio
-
American Portfolios Advisors Holbrook, NY6.38KShares$00.0% of portfolio
-
Concourse Financial Group Securities, Inc. Birmingham, AL0Shares$00.0% of portfolio
Latest Institutional Activity in ORTX
Top Purchases
Top Sells
About ORTX
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. It has a strategic collaboration agreement with Pharming Group N.V. for research, development, manufacturing, and commercialization of OTL-105, an investigational ex vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.
Insider Transactions at ORTX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 24
2024
|
Charles A Rowland Jr |
SELL
Sale (or disposition) back to the issuer
|
Direct |
12,294
-100.0%
|
-
|
|
Jan 24
2024
|
Frank E Thomas |
SELL
Sale (or disposition) back to the issuer
|
Direct |
92,081
-100.0%
|
-
|
|
Jan 24
2024
|
James A Geraghty |
SELL
Sale (or disposition) back to the issuer
|
Direct |
44,391
-100.0%
|
-
|
|
Jan 24
2024
|
Joanne T. Beck |
SELL
Sale (or disposition) back to the issuer
|
Direct |
9,294
-100.0%
|
-
|
|
Jan 24
2024
|
Marc Dunoyer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
37,179
-100.0%
|
-
|
|
Jan 24
2024
|
Bobby Gaspar Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
366,158
-100.0%
|
-
|
|
Mar 10
2023
|
Frank E Thomas |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+17.84%
|
$0
$0.46 P/Share
|
|
Feb 09
2023
|
Frank E Thomas |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+21.72%
|
$0
$0.46 P/Share
|
|
Apr 01
2022
|
Bobby Gaspar Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
15,000
+3.94%
|
$0
$0.74 P/Share
|
|
Apr 01
2022
|
Frank E Thomas |
BUY
Open market or private purchase
|
Direct |
10,000
+16.11%
|
$0
$0.75 P/Share
|
|
Feb 19
2021
|
Fmr LLC > 10% Shareholder |
SELL
Conversion of derivative security
|
Indirect |
819,704
-9.09%
|
-
|
|
Feb 05
2021
|
Fmr LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
2,045,510
-16.71%
|
$12,273,060
$6.98 P/Share
|
|
Jan 29
2021
|
Frank E Thomas |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+19.2%
|
$20,000
$2.44 P/Share
|
|
Jan 11
2021
|
Bobby Gaspar Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,411
-0.96%
|
$20,466
$6.72 P/Share
|
|
Jan 11
2021
|
Frank E Thomas |
SELL
Payment of exercise price or tax liability
|
Direct |
3,706
-10.36%
|
$22,236
$6.72 P/Share
|
|
Jan 08
2021
|
Bobby Gaspar Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,250
+1.73%
|
-
|
|
Jan 08
2021
|
Frank E Thomas |
BUY
Grant, award, or other acquisition
|
Direct |
10,667
+22.96%
|
-
|
|
Sep 24
2020
|
Ra Capital Management, L.P. Director |
BUY
Open market or private purchase
|
Indirect |
473,327
+4.57%
|
$1,893,308
$4.61 P/Share
|
|
Aug 21
2020
|
Ra Capital Management, L.P. Director |
BUY
Open market or private purchase
|
Indirect |
64,642
+0.34%
|
$258,568
$4.58 P/Share
|
|
Aug 20
2020
|
Ra Capital Management, L.P. Director |
BUY
Open market or private purchase
|
Indirect |
62,631
+0.33%
|
$250,524
$4.61 P/Share
|
Last 12 Months Summary
| Sale (or disposition) back to the issuer | 561K shares |
|---|